Literature DB >> 21358682

G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT.

Y-C Su1, S-C Li, C-K Hsu, C-C Yu, T-J Lin, C-Y Lee, H-F Liao.   

Abstract

In G-CSF-mobilized hematopoietic SCT (HSCT), natural killer (NK) cells have a critical role in GVHD and GVL effects. However, regulation of NK cell response to G-CSF remains unclear. This study assayed G-CSF effects in both HSCT donors and NK-92MI cells. The donors who received G-CSF had significantly decreased NK cell cytotoxicity. Levels of phosphatidylinositol 3-kinase (PI3K) and phosphorylated (p)-Akt, but not mammalian target of rapamycin (mTOR), were downregulated in NK cells from G-CSF-injected donors. G-CSF also decreased cytotoxicity without affecting viability and NF-κB of NK-92MI cells. PI3K and p-ERK expression were also decreased in G-CSF-treated NK-92MI cells, and their inhibitors, wortmannin and PD98059, respectively, both enhanced the downregulation of cytotoxicity. These effects were accompanied by decreased expression of a cytotoxicity-related gene, triosephosphate isomerase (TPI). Wortmannin, but not PD98059, enhanced the downregulation of TPI in G-CSF-treated NK-92MI cells, indicating a correlation between PI3K and TPI. We conclude that G-CSF-impaired NK cell cytotoxicity may accompany PI3K/Akt signaling. The effect is transient and NK cells may recover after G-CSF clearance, suggesting that G-CSF-mobilized HSCT may benefit both acute GVHD prevention and late-phase GVL promotion in HSCT recipients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21358682     DOI: 10.1038/bmt.2011.22

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  15 in total

Review 1.  Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.

Authors:  F Saraceni; N Shem-Tov; A Olivieri; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

2.  Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort.

Authors:  Z Gul; E Van Meter; M Abidi; I Ditah; M Abdul-Hussein; A Deol; L Ayash; L G Lum; E K Waller; V Ratanatharathorn; J Uberti; Z Al-Kadhimi
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

3.  Effect of the in vivo application of granulocyte colony-stimulating factor on NK cells in bone marrow and peripheral blood.

Authors:  Xing-Xing Yu; Ting-Ting Han; Ling-Ling Xu; Ying-Jun Chang; Xiao-Jun Huang; Xiang-Yu Zhao
Journal:  J Cell Mol Med       Date:  2018-03-25       Impact factor: 5.310

4.  Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice.

Authors:  Heba H Mostafa; Peter Vogel; Ashok Srinivasan; Charles J Russell
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

Review 5.  Hematopoietic stem cell donation.

Authors:  Shu-Huey Chen; Tso-Fu Wang; Kuo-Liang Yang
Journal:  Int J Hematol       Date:  2013-02-19       Impact factor: 2.490

6.  Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.

Authors:  Yu Xiong; Manon Mouginot; Loic Reppel; Chongsheng Qian; Jean-Francois Stoltz; Danièle Bensoussan; Véronique Decot
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

7.  Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.

Authors:  Nina Orfali; Mei-Jie Zhang; Mariam Allbee-Johnson; Jaap Jan Boelens; Andrew S Artz; Claudio G Brunstein; Ian K McNiece; Filippo Milano; Muhammad Bilal Abid; Lynette Chee; Miguel A Diaz; Michael R Grunwald; Peiman Hematti; Jingmei Hsu; Hillard M Lazarus; Pashna N Munshi; Timothy Prestidge; Olle Ringden; David Rizzieri; Marcie L Riches; Sachiko Seo; Melhem Solh; Scott Solomon; David Szwajcer; Jean Yared; Koen van Besien; Mary Eapen
Journal:  Transplant Cell Ther       Date:  2021-10-02

8.  Neutrophils with protumor potential could efficiently suppress tumor growth after cytokine priming and in presence of normal NK cells.

Authors:  Rui Sun; Jing Luo; Dong Li; Yu Shu; Chao Luo; Shan-Shan Wang; Jian Qin; Gui-Mei Zhang; Zuo-Hua Feng
Journal:  Oncotarget       Date:  2014-12-30

Review 9.  G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation.

Authors:  Ioannis Karagiannidis; Eralda Salataj; Erika Said Abu Egal; Ellen J Beswick
Journal:  Cytokine       Date:  2021-03-04       Impact factor: 3.926

10.  The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma.

Authors:  Sara Pessina; Gabriele Cantini; Dimos Kapetis; Emanuela Cazzato; Natalia Di Ianni; Gaetano Finocchiaro; Serena Pellegatta
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.